Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof

Patent metadata

Field	Value
Publication number	US-9822181-B2
Application number	US-201414913632-A
Country	US
Kind code	B2
Filing date	Aug 20, 2014
Priority date	Aug 23, 2013
Publication date	Nov 21, 2017
Grant date	Nov 21, 2017

Abstract

The present invention is directed to sequence-optimized CD 123×CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD 123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.

First claim

What is claimed is:

1. A sequence-optimized diabody capable of specific binding to an epitope of CD123 and to an epitope of CD3, wherein the diabody comprises a first polypeptide chain and a second polypeptide chain, covalently bonded to one another, wherein:
A. the first polypeptide chain comprises, in the N-terminal to C-terminal direction:
i. a Domain 1, comprising
(1) a sub-Domain (1A), which comprises a VL Domain of a monoclonal antibody capable of binding to CD3 (VL CD3 ) (SEQ ID NO:21); and
(2) a sub-Domain (1B), which comprises a VH Domain of a monoclonal antibody capable of binding to CD123(VH CD123 ) (SEQ ID NO:26),
wherein said sub-Domains 1A and 1B are separated from one another by a peptide linker (SEQ ID NO:29);

ii. a Domain 2, wherein said Domain 2 is an E-coil Domain (SEQ ID NO:34) or a K-coil Domain (SEQ ID NO:35), wherein said Domain 2 is separated from said Domain 1 by a peptide linker (SEQ ID NO:30); and

B. the second polypeptide chain comprises, in the N-terminal to C-terminal direction:
i. a Domain 1, comprising
(1) a sub-Domain (1A), which comprises a VL Domain of a monoclonal antibody capable of binding to CD123(VL CD123 ) (SEQ ID NO:25); and
(2) a sub-Domain (1B), which comprises a VH Domain of a monoclonal antibody capable of binding to CD3 (VH CD3 ) (SEQ ID NO:22),
wherein said sub-Domains 1A and 1B are separated from one another by a peptide linker (SEQ ID NO:29);

ii. a Domain 2, wherein said Domain 2 is a K-coil Domain (SEQ ID NO:35) or an E-coil Domain (SEQ ID NO:34), wherein said Domain 2 is separated from said Domain 1 by a peptide linker (SEQ ID NO:30); and wherein said Domain 2 of said first and said second polypeptide chains are not both E-coil Domains or both K-coil Domains;

and wherein:
(a) said VL Domain of said first polypeptide chain and said VH Domain of said second polypeptide chain form an Antigen Binding Domain capable of specifically binding to an epitope of CD3; and
(b) said VL Domain of said second polypeptide chain and said VH Domain of said first polypeptide chain form an Antigen Binding Domain capable of specifically binding to an epitope of CD123.

2. The diabody of claim 1 , wherein said first polypeptide chain additionally comprises an Albumin-Binding Domain (SEQ ID NO:36) linked to said Domain 2 via a peptide linker (SEQ ID NO:31).

3. The diabody of claim 1 , wherein said second polypeptide chain additionally comprises a Domain 3 comprising a CH2 and CH3 Domain of an immunoglobulin Fc Domain (SEQ ID NO:37), wherein said Domain 3 is linked to said Domain 1 via a peptide linker (SEQ ID NO:33).

4. The diabody of claim 1 , wherein said second polypeptide chain additionally comprises a Domain 3 comprising a CH2 and CH3 Domain of an immunoglobulin Fc Domain (SEQ ID NO:37), wherein said Domain 3 is linked to said Domain 2 via a peptide linker (SEQ ID NO:32).

5. The diabody of claim 1 , wherein said Domain 2 of said first polypeptide chain is a K-coil Domain (SEQ ID NO:35) and said Domain 2 of said second polypeptide chain is an E-coil Domain (SEQ ID NO:34).

6. The diabody of claim 1 , wherein said Domain 2 of said first polypeptide chain is an E-coil Domain (SEQ ID NO:34) and said Domain 2 of said second polypeptide chain is a K-coil Domain (SEQ ID NO:35).

7. The diabody of claim 1 , wherein the diabody is capable of cross-reacting with both human and primate CD123 and CD3 proteins.

8. A bi-specific diabody capable of specific binding to an epitope of CD123 and to an epitope of CD3, wherein the diabody comprises a first polypeptide chain and a second polypeptide chain, covalently bonded to one another, wherein said bi-specific diabody comprises:
A. a first polypeptide chain having the amino acid sequence of SEQ ID NO:1; and
B. a second polypeptide chain having the amino acid sequence of SEQ ID NO:3;
wherein said first and said second polypeptide chains are covalently bonded to one another by a disulfide bond.

9. A pharmaceutical composition comprising the diabody of claim 1 , and a physiologically acceptable carrier.

10. A method for the treatment of a disease or condition associated with or characterized by the expression of CD123, wherein said method comprises administering a therapeutically effective amount of the pharmaceutical composition of claim 9 to a recipient in need of such treatment.

11. The method of claim 10 , wherein said disease or condition associated with or characterized by the expression of CD123 is cancer.

12. The method of claim 11 , wherein said cancer is selected from the group consisting of: acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), including blastic crisis of CML and Abelson oncogene associated with CML (Bcr-ABL translocation), myelodysplastic syndrome (MDS), acute B lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), including Richter's syndrome or Richter's transformation of CLL, hairy cell leukemia (HCL), blastic plasmacytoid dendritic cell neoplasm (BPDCN), non-Hodgkin lymphomas (NHL), including mantel cell leukemia (MCL), and small lymphocytic lymphoma (SLL), Hodgkin's lymphoma, systemic mastocytosis, and Burkitt's lymphoma.

13. The method of claim 10 , wherein said disease or condition associated with or characterized by the expression of CD123 is an inflammatory condition.

14. The method of claim 13 , wherein said inflammatory condition is selected from the group consisting of: Autoimmune Lupus (SLE), allergy and asthma, rheumatoid arthritis.

15. A pharmaceutical composition comprising the diabody of claim 8 , and a physiologically acceptable carrier.

16. A method for the treatment of a disease or condition associated with or characterized by the expression of CD123, wherein said method comprises administering a therapeutically effective amount of the pharmaceutical composition of claim 15 to a recipient in need of such treatment.

17. The method of claim 16 , wherein said disease or condition associated with or characterized by the expression of CD123 is cancer.

18. The method of claim 17 , wherein said cancer is selected from the group consisting of: acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), including blastic crisis of CML and Abelson oncogene associated with CML (Bcr-ABL translocation), myelodysplastic syndrome (MDS), acute B lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), including Richter's syndrome or Richter's transformation of CLL, hairy cell leukemia (HCL), blastic plasmacytoid dendritic cell neoplasm (BPDCN), non-Hodgkin lymphomas (NHL), including mantel cell leukemia (MCL), and small lymphocytic lymphoma (SLL), Hodgkin's lymphoma, systemic mastocytosis, and Burkitt's lymphoma.

19. The method of claim 16 , wherein said disease or condition associated with or characterized by the expression of CD123 is an inflammatory condition.

20. The method of claim 19 , wherein said inflammatory condition is selected from the group consisting of: Autoimmune Lupus (SLE), allergy and asthma.

21. The diabody of claim 1 , wherein said first polypeptide chain additionally comprises a Domain 3 comprising a CH2 and CH3 Domain of an immunoglobulin Fc Domain (SEQ ID NO:37), wherein said Domain 3 is linked to said Domain 1 via a peptide linker (SEQ ID NO:33).

22. The diabody of claim 1 , wherein said first polypeptide chain additionally comprises a Domain 3 comprising a CH2 and CH3 Domain of an immunoglobulin Fc Domain (SEQ ID NO:37), wherein said Domain 3 is linked to said Domain 2 via a peptide linker (SEQ ID NO:

Assignees

• Macrogenics Inc

Inventors

• Bonvini Ezio
• Johnson Leslie S
• Huang Ling
• Moore Paul A
• Chichili Gurunadh Reddy
• Alderson Ralph Froman

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title